Aspira Pathlab & Diagnostics L
Latest filings
- Quarterly compliance certificate for share dematerialisation filed with BSE · Compliance
- Promoter buys 245 shares of Aspira Pathlab via open market · Ownership Changes
- Promoter Jay Bhanushali buys 1,424 Aspira Pathlab shares via open market · Ownership Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
A Healthcare Services company listed on BSE, reporting revenue of ₹23 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY25 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from Aspira Pathlab & Diagnostics L's filed financials and exchange disclosures
What does Aspira Pathlab & Diagnostics L do?
Aspira Pathlab & Diagnostics L is a Healthcare Services company listed on BSE.
Is Aspira Pathlab & Diagnostics L profitable?
Yes. Over the trailing twelve months Aspira Pathlab & Diagnostics L reported a net profit of ₹2.40 Cr on revenue of ₹23 Cr.
Does Aspira Pathlab & Diagnostics L pay a dividend?
Not in the latest reported year — Aspira Pathlab & Diagnostics L's dividend payout for FY25 was nil.
Is Aspira Pathlab & Diagnostics L debt-free?
On a net basis, yes. It reported borrowings of ₹1.21 Cr on its 31 Mar 2025 balance sheet, but holds ₹0.55 Cr more cash than debt.
Is Aspira Pathlab & Diagnostics L expensive compared with its peers?
On trailing P/E, Aspira Pathlab & Diagnostics L ranks 18 of 25 in Healthcare Service Provider — cheaper than 29% of them, against an industry median of 23.6×. This is a position, not a valuation judgement.
How much does the Aspira Pathlab & Diagnostics L share price move in a day?
On a typical session Aspira Pathlab & Diagnostics L moves 2.19% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track Aspira Pathlab & Diagnostics L's announcements?
Every NSE and BSE filing by Aspira Pathlab & Diagnostics L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.